The FDA is expected to decide by January 10, 2027, after a Phase III study showed Enspryng reduced the risk of MOGAD relapse by 68% versus placebo.
Key Investor Takeaways
- Genentech, part of Roche (USOTC:RHHBY), received FDA Priority Review for an Enspryng supplemental Biologics License Application covering MOGAD.
- The Phase III METEOROID trial showed a 68% reduction in relapse risk versus placebo, meeting its primary endpoint.
- At 48 weeks, 87% of Enspryng-treated patients were relapse-free compared with 67% receiving placebo.
- An FDA decision is expected by January 10, 2027, creating a defined regulatory catalyst for Roche.
- There are currently no approved treatments for MOGAD, and Enspryng would become the first disease-modifying therapy for the condition if approved.
Why RHHBY Stock Is in Focus
The FDA granted Priority Review to Genentech’s application seeking to expand Enspryng into myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, a rare autoimmune disorder affecting the central nervous system.
The regulatory filing is supported by the Phase III METEOROID study. Enspryng reduced the risk of a new MOGAD relapse by 68% compared with placebo, with a p-value of 0.0025. The study also reported improvements in annualized relapse rates, MRI lesion activity and use of rescue therapy.
Safety findings were consistent with more than a decade of clinical trial and post-approval experience with Enspryng in neuromyelitis optica spectrum disorder.
Regulatory review is also progressing outside the U.S. The European Medicines Agency has validated the MOGAD application, with a European Commission decision expected in the third quarter of 2027.
Why This Matters for Investors
Priority Review moves Enspryng closer to a potential expansion into a neurological disease for which no treatments are currently approved.
If cleared, Enspryng would become the first disease-modifying therapy approved for MOGAD. That could broaden the drug’s role beyond its existing use in neuromyelitis optica spectrum disorder, where it is approved in approximately 90 countries and has been used in more than 10,000 patients.
The METEOROID results also provide clinical evidence supporting the regulatory application, while the established safety experience in another neurological autoimmune condition may provide additional context for regulators reviewing the new indication.
For Roche investors, the MOGAD filing is part of a broader effort to extend Enspryng into additional autoimmune and inflammatory diseases. The company is also developing the therapy for autoimmune encephalitis and thyroid eye disease.
What to Watch Next
The main near-term catalyst is the FDA’s MOGAD decision, expected by January 10, 2027.
Before then, Enspryng has another regulatory milestone: the FDA is expected to decide on its supplemental application for thyroid eye disease in October 2026 following Priority Review granted in June.
Investors can also watch the European MOGAD review, where a European Commission decision is expected in the third quarter of 2027.